Shimmer and ClearSky Announce Partnership
Shimmer Research, provider of wearable wireless sensor products and solutions, and ClearSky Medical Diagnostics, a company that specializes in medical devices for the diagnosis and monitoring of neurodegenerative conditions, announced they are partnering to bring a new level of analytic capabilities to the use of wearable sensors in clinical research. This partnership will employ Shimmer’s Verisense wearable sensors platform with ClearSky algorithms and machine learning.
Verisense is a solution for reliably capturing accurate and complete biometric data. Worn on the wrist, the Verisense Inertial Measurement Unit (IMU) sensor can monitor activity and sleep. But Verisense can be used for any IMU application with up to seven sensors worn on different parts of a participant’s body, making it invaluable for studying complex musculoskeletal or neurological conditions, such as dystonia or epilepsy.
ClearSky Medical Diagnostics specializes in developing technologies for the diagnosis and monitoring of Parkinson’s disease, Alzheimer’s disease and other neurodegenerative conditions. Its clinically-validated medical devices have been used in medical centers worldwide and in clinical trials to demonstrate the efficacy of new drugs.
For more information, visit www.clearskymd.com or www.shimmersensing.com
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
